Stay updated on Cabozantinib and Durvalumab Immuno-oncology Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib and Durvalumab Immuno-oncology Clinical Trial page.

Latest updates to the Cabozantinib and Durvalumab Immuno-oncology Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedNo significant additions or deletions were observed on the ARCADIA study page. The published study details remain unchanged.SummaryDifference0.4%

- Check31 days agoChange DetectedMajor update: adds current operating status notice and links for NIH Clinical Center, and bumps version to v3.2.0, replacing the old v3.1.0.SummaryDifference2%

- Check38 days agoChange DetectedPage revision updated to v3.1.0 with new contact emails added; v3.0.2 removed. No clear changes to pricing or stock detected.SummaryDifference0.1%

- Check53 days agoChange DetectedThe page now shows Revision: v3.0.2, replacing v3.0.1, and the 'Back to Top' link has been removed.SummaryDifference0.1%

- Check60 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.1%

- Check67 days agoChange DetectedThe web page has updated its facility name and location to Milan, Italy, and has added specific drug names, including cabozantinib and durvalumab, while removing several related medical topics and previous location details.SummaryDifference1%

Stay in the know with updates to Cabozantinib and Durvalumab Immuno-oncology Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib and Durvalumab Immuno-oncology Clinical Trial page.